Subdermal Contraceptive Implants Market Report Scope & Overview:
The Subdermal Contraceptive Implants Market was valued at USD 1.03 billion in 2023 and is expected to reach USD 2.01 billion by 2032, growing at a CAGR of 7.76% from 2024-2032.
To Get more information on Subdermal Contraceptive Implants Market - Request Free Sample Report
The Subdermal Contraceptive Implants Market report presents a unique view by centering around the incidence and prevalence of unintended pregnancy and increasing usage of long-acting reversible contraceptives such as subdermal implants. The report offers a thorough examination of prescription trends geographically, showing geographical variations in implant usage. The study also touches on patterns of healthcare expenditure, such as government, commercial, private, and out-of-pocket expenses, to evaluate market accessibility. It further discusses adoption and demographics and considers the extent to which factors such as age, socioeconomic status, and education contribute to the utilization of subdermal contraceptive implants across various markets.
The U.S. Subdermal Contraceptive Implants Market was valued at USD 0.44 billion in 2023 and is expected to reach USD 0.85 billion by 2032, growing at a CAGR of 7.59% from 2024-2032. The United States is the leading player in North America's Subdermal Contraceptive Implants Market, with the highest share because of its superior healthcare infrastructure, extensive availability of contraceptives, and high consumer awareness. The emphasis on reproductive health in the country, along with government and healthcare provider efforts, strongly enhances the use of subdermal contraceptive implants. The US market also enjoys high per capita healthcare expenditure, providing access to advanced contraceptive solutions.
Market Dynamics
Drivers
The growing demand for long-acting reversible contraceptives (LARCs), including subdermal implants, is a major market driver.
Subdermal implants provide an effective and convenient method of birth control with minimal user intervention after insertion. With a lifespan of 3 to 5 years, they provide an advantage over daily or monthly options, leading to their growing popularity, particularly in developed markets like North America and Europe. As per the Centers for Disease Control and Prevention (CDC), LARCs constituted around 10% of all contraceptive use in the U.S. in 2020. With increased awareness worldwide, more women are increasingly turning to these implants, which is driving faster market growth. In addition to this, awareness programs conducted by organizations like the WHO and Family Planning Associations are encouraging the uptake of LARCs in developing countries.
Government Initiatives and Support for Family Planning are driving the market growth.
Government funding and support for family planning programs are driving the Subdermal Contraceptive Implants Market. Most nations are investing in reproductive health programs, including subsidized access to modern methods of contraception, particularly in middle- and low-income countries. For example, in October 2023, Shanghai Dahua Pharmaceutical Co., Ltd. joined hands with DKT WomanCare to lower the cost of its Levoplant contraceptive implant, so it is accessible at a low price for poor communities. The United Nations Population Fund (UNFPA) says that over 60% of women in developing nations use government-provided contraceptives. This assistance, accompanied by measures to combat high levels of unplanned pregnancies worldwide, is spurring increased use of subdermal implants as an affordable, long-lasting method.
Restraint
High Initial Cost and Accessibility Barriers are restraining the market growth.
One of the major constraints for the Subdermal Contraceptive Implants Market is the initial expense and accessibility constraints in low-income areas. Although the overall cost of subdermal implants over time is less than other means, the initial expense of the procedure and the implant itself may be too high for most women, especially in developing nations. While some governments and non-profit entities are attempting to make these implants more accessible, they are not yet widely accessible. In many areas, trained healthcare personnel to place the implants are in short supply, and in rural areas, it is difficult for people to find healthcare facilities to go to. This results in underutilization of existing forms of contraception, which restricts the potential of the market. Furthermore, social and cultural elements may further contribute to access problems in some communities, decelerating adoption.
Opportunities
Expansion in Emerging Markets is presenting a significant opportunity to the market.
One of the major opportunities for the Subdermal Contraceptive Implants Market is to widen access to developing markets, especially in Asia Pacific, Latin America, and Africa. With the growing populations, developing family planning awareness, and rising government support for reproductive health, these markets offer untapped potential for subdermal implants. In nations such as India, Brazil, and certain regions of Sub-Saharan Africa, initiatives towards the development of healthcare facilities and the provision of subsidized family planning measures provide a conducive environment for the uptake of subdermal implants. Moreover, global institutions like the United Nations Population Fund (UNFPA) are actively engaged in increasing access to family planning interventions, including subdermal implants, which provide new opportunities for the expansion of markets in such fast-developing regions.
Challenges
Social and Cultural Resistance challenging the progress of the market.
One of the major threats to the Subdermal Contraceptive Implants Market is social and cultural resistance towards the acceptance of new contraceptive technologies, particularly in conservative cultures. In certain cultures, mostly in Africa, the Middle East, and Asia, cultural and religious factors could play a role in shaping attitudes towards family planning, creating unwillingness to use contraceptive methods such as subdermal implants. Misconceptions regarding the implants, such as fears over side effects or long-term health effects, also hinder their uptake. Moreover, miscommunication and poor counseling by doctors further contribute to the issue, restraining the expansion of the market. The key to greater uptake and penetration into the market is overcoming these cultural barriers by launching awareness programs and community outreach.
Segmentation Analysis
By Product
In 2023, the Etonogestrel Implant segment dominated the Subdermal Contraceptive Implants Market with 63.10% market share. This is due to several leading factors. Etonogestrel implants like Nexplanon are highly effective long-acting reversible contraceptives (LARCs), which are given for a period of up to three years with over 99% effectiveness in preventing pregnancy. They are "set-it-and-forget-it" products that people who want a low-fuss contraceptive find most appealing. Also, the design of the implant as a single, flexible rod makes insertion and removal easier, increasing user convenience. The high availability and increasing awareness of Etonogestrel implants, especially in developed countries, have also driven their uptake. Furthermore, continued efforts by manufacturers to increase access and affordability, along with support from healthcare providers, have cemented the Etonogestrel Implant segment's market-leading position.
By Distribution Channel
In 2023, the Hospital segment dominated the Subdermal Contraceptive Implants Market by distribution channel with a 55.19% market share because of the availability of extensive medical infrastructure and qualified professionals required to carry out implant procedures. Hospitals are the most important point of care for women in need of long-term contraceptive measures, particularly in urban regions where highly advanced reproductive healthcare services are available. Hospitals tend to be incorporated within national family planning programs and collaborations with institutions such as the WHO and UNFPA to maintain a steady supply of implants at subsidized costs. Such institutions also serve a large population base, including high-risk or complicated cases necessitating specialized medical care during and following the insertion process. The capacity of hospitals to manage both outpatient and inpatient services, as well as postoperative services, has further entrenched their control over implant distribution.
The Gynecology Clinics segment experience the fastest growth over the forecast period with 8.25% CAGR as a result of their growing accessibility, specialization, and patient-friendliness. These clinics provide a more intimate, low-key, and time-saving setting for women who want contraceptive consultation and treatment, an attractive option to hospitals. As women's health awareness grows, especially in cities and semi-cities, increasing numbers of women are approaching gynecology clinics for reproductive healthcare, including subdermal implant consultation. Additionally, the increasing popularity of private clinics and chain clinics dedicated to women's health has increased the availability of services. Such clinics are also more adaptable to new technologies and to marketing newer methods of contraception, which adds to their anticipated high growth rate.
Regional Analysis
North America dominated the Subdermal Contraceptive Implants Market with a 63.10% market share in 2023, owing to several primary factors such as high expenditure on healthcare, strong healthcare infrastructure, and improved access to sophisticated contraceptive technologies. The region is aided by robust regulatory systems that assure the safety and effectiveness of medical products, thus increasing consumer trust in implantable contraceptives. Also, North America possesses a large number of healthcare professionals and specialized clinics that advocate the utilization of long-acting reversible contraceptives (LARCs), such as subdermal implants, which are gaining popularity because they are convenient and effective. The increasing level of awareness regarding family planning, along with a high need for dependable birth control products, further supports the region's leadership in the market.
Asia Pacific is the fastest-growing region in the Subdermal Contraceptive Implants market with 8.60% CAGR throughout the forecast period, spurred on by drivers such as rising population, expanding healthcare access, and changing social norms. In much of Asia, there is an emerging emphasis on reproductive health and family planning, supplemented by government support encouraging the use of contraceptives. Having a high and heterogeneous population, Asia Pacific countries are experiencing large changes towards newer forms of contraceptives such as subdermal implants, particularly in rural and remote locations where older forms are not as available. In addition, urbanization and the increasing middle class in India, China, and Southeast Asia are driving the demand for convenient, long-term contraceptives, further boosting the growth rate of the market at a fast pace.
Get Customized Report as per Your Business Requirement - Enquiry Now
Key Market Players
Bayer AG (Nexplanon, Implanon NXT)
Merck & Co., Inc. (Implanon, Organon Nexplanon)
Shanghai Dahua Pharmaceutical Co., Ltd. (Sino-implant (II), Levoplant)
Pfizer Inc. (Sayana Press, Depo-Provera)
Mithra Pharmaceuticals (Estelle, Donesta)
HLL Lifecare Limited (Mala-N, Norplant)
SmPC Ltd. (Norplant, Levonorgestrel Implant)
Zhejiang Xianju Pharmaceutical Co., Ltd. (Levonorgestrel Implant, Xianju Contraceptive Stick)
Shanghai Pharmaceutical Co., Ltd. (Levonorgestrel Subdermal Implant, SP Implant II)
Reckitt Benckiser Group plc (Durex Invisible, Durex RealFeel — supporting sexual health segment)
Mylan N.V. (a Viatris company) (Medroxyprogesterone Acetate Injectable, Mylimplant)
Gedeon Richter Plc. (Levonorgestrel-Releasing Implant, Rigevidon Support Implant)
Teva Pharmaceutical Industries Ltd. (Plan B One-Step, Levonorgestrel Implant)
Actavis (a division of Teva) (NorLevo, Subdermal Levonorgestrel Implant)
Johnson & Johnson Services, Inc. (Evra Patch, ORTHO EVRA)
Sino Biopharmaceutical Limited (Subdermal Contraceptive Implant, Levonorgestrel Insertion Kit)
BioFarma S.p.A. (Levonorgestrel Subdermal Rod, BioPlant-Rod)
Population Council (Levoplant, Norplant)
Piramal Enterprises Ltd. (Contraceptive Implant System, FemProtect)
Cipla Ltd. (Ciplimplant, Levogest Implant)
Suppliers (These suppliers primarily provide biocompatible polymers, excipients, and specialized chemical formulations used in the manufacturing of subdermal contraceptive implants, ensuring controlled drug release, stability, and safety for extended durations.) In the Subdermal Contraceptive Implants Market.
BASF SE
Eastman Chemical Company
Evonik Industries AG
Covestro AG
Dow Inc.
Lubrizol Corporation
Mitsubishi Chemical Corporation
Solvay S.A.
DSM Nutritional Products
Corbion N.V.
Recent Development
February 2024: Bayer AG allied with Daré Bioscience to create a hormone-free monthly contraceptive. This deal is to broaden the options available in the non-hormonal contraceptives category, and this may make a big difference in the subdermal contraceptive implants market.
February 2023: The Family Planning Association of India (FPAI) promoted the use of Implanon NXT, a single-rod subdermal contraceptive implant marketed by Organon, a spin-off of Merck & Co., Inc., indicating Merck's indirect contribution to promoting subdermal contraceptive options.
October 2023: Shanghai Dahua Pharmaceutical Co., Ltd., in collaboration with DKT WomanCare, cut the price of its two-rod contraceptive implant, Levoplant, to around USD 6 for qualifying purchasers. This effort is aimed at increasing access to high-quality contraceptives, especially in low-income areas.
| Report Attributes | Details |
|---|---|
| Market Size in 2023 | US$ 1.03 Billion |
| Market Size by 2032 | US$ 2.01 Billion |
| CAGR | CAGR of 7.76 % From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product (Etonogestrel Implant, Levonorgestrel Implant) • By Distribution Channel (Hospital, Gynecology Clinics, Community Health Care Centers, Others) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
| Company Profiles | Bayer AG, Merck & Co., Inc., Shanghai Dahua Pharmaceutical Co., Ltd., Pfizer Inc., Mithra Pharmaceuticals, HLL Lifecare Limited, SmPC Ltd., Zhejiang Xianju Pharmaceutical Co., Ltd., Shanghai Pharmaceutical Co., Ltd., Reckitt Benckiser Group plc, Mylan N.V. (a Viatris company), Gedeon Richter Plc., Teva Pharmaceutical Industries Ltd., Actavis (a division of Teva), Johnson & Johnson Services, Inc., Sino Biopharmaceutical Limited, BioFarma S.p.A., Population Council, Piramal Enterprises Ltd., Cipla Ltd. |
Ans: The Subdermal Contraceptive Implants Market is expected to grow at a CAGR of 7.76% from 2024-2032.
Ans: The Subdermal Contraceptive Implants Market was USD 1.03 billion in 2023 and is expected to reach USD 2.01 billion by 2032.
Ans: The growing demand for long-acting reversible contraceptives (LARCs), including subdermal implants, is a major market driver.
Ans: The “Hospital” segment dominated the Subdermal Contraceptive Implants Market.
Ans: North America dominated the Subdermal Contraceptive Implants Market in 2023.
Table of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends (2023), by Region
5.3 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket) (2023)
5.4 Adoption Rates and Demographics (2023)
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Subdermal Contraceptive Implants Market Segmentation, by Product
7.1 Chapter Overview
7.2 Etonogestrel Implants
7.2.1 Etonogestrel Implants Market Trends Analysis (2020-2032)
7.2.2 Etonogestrel Implants Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Levonorgestrel Implant
7.3.1 Levonorgestrel Implant Market Trends Analysis (2020-2032)
7.3.2 Levonorgestrel Implant Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Subdermal Contraceptive Implants Market Segmentation, By Distribution Channel
8.1 Chapter Overview
8.2 Hospitals
8.2.1 Hospitals Market Trends Analysis (2020-2032)
8.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Gynecology Clinics
8.3.1 Long-term Care Centers Market Trends Analysis (2020-2032)
8.3.2 Long-term Care Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Community Health Care Centers
8.4.1 Community Health Care Centers Market Trends Analysis (2020-2032)
8.4.2 Community Health Care Centers Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Others
8.5.1 Others Market Trends Analysis (2020-2032)
8.5.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.2.3 North America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.4 North America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.2.5 USA
9.2.5.1 USA Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.5.2 USA Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.2.6 Canada
9.2.6.1 Canada Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.6.2 Canada Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.2.7 Mexico
9.2.7.1 Mexico Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.7.2 Mexico Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.1.3 Eastern Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.4 Eastern Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.5 Poland
9.3.1.5.1 Poland Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.5.2 Poland Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.6 Romania
9.3.1.6.1 Romania Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.6.2 Romania Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.7.2 Hungary Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.8.2 Turkey Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.1.9.2 Rest of Eastern Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.3.2.3 Western Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.4 Western Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.5 Germany
9.3.2.5.1 Germany Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.5.2 Germany Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.6 France
9.3.2.6.1 France Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.6.2 France Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.7 UK
9.3.2.7.1 UK Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.7.2 UK Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.8 Italy
9.3.2.8.1 Italy Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.8.2 Italy Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.9 Spain
9.3.2.9.1 Spain Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.9.2 Spain Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.10.2 Netherlands Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.11.2 Switzerland Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.12 Austria
9.3.2.12.1 Austria Healthcare Predictive Analytic Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.12.2 Austria Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.3.2.13.2 Rest of Western Europe Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Subdermal Contraceptive Implants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.4.3 Asia Pacific Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.4 Asia Pacific Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.5 China
9.4.5.1 China Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 China Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.6 India
9.4.5.1 India Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 India Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.5 Japan
9.4.5.1 Japan Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.5.2 Japan Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.6 South Korea
9.4.6.1 South Korea Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.6.2 South Korea Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.7 Vietnam
9.4.7.1 Vietnam Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.2.7.2 Vietnam Healthcare Predictive Analytic Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.8 Singapore
9.4.8.1 Singapore Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.8.2 Singapore Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.9 Australia
9.4.9.1 Australia Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.9.2 Australia Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.4.10.2 Rest of Asia Pacific Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Subdermal Contraceptive Implants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.1.3 Middle East Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.4 Middle East Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.5 UAE
9.5.1.5.1 UAE Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.5.2 UAE Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.6.2 Egypt Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.7.2 Saudi Arabia Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.8.2 Qatar Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.1.9.2 Rest of Middle East Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.5.2.3 Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.4 Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.5.2 South Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.6.2 Nigeria Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.5.2.7 Rest of Africa
9.5.2.7.1 Rest of Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.5.2.7.2 Rest of Africa Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
9.6.3 Latin America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.4 Latin America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.5 Brazil
9.6.5.1 Brazil Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.5.2 Brazil Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.6 Argentina
9.6.6.1 Argentina Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.6.2 Argentina Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.7 Colombia
9.6.7.1 Colombia Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.7.2 Colombia Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Product (2020-2032) (USD Billion)
9.6.8.2 Rest of Latin America Subdermal Contraceptive Implants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10. Company Profiles
10.1 Bayer AG
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Products/ Services Offered
110.1.4 SWOT Analysis
10.2 Merck & Co., Inc.
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Products/ Services Offered
10.2.4 SWOT Analysis
10.3 Shanghai Dahua Pharmaceutical Co., Ltd.
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Products/ Services Offered
10.3.4 SWOT Analysis
10.4 Pfizer Inc.
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Products/ Services Offered
10.4.4 SWOT Analysis
10.5 Mithra Pharmaceuticals
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Products/ Services Offered
10.5.4 SWOT Analysis
10.6 HLL Lifecare Limited
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Products/ Services Offered
10.6.4 SWOT Analysis
10.7 SmPC Ltd.
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Products/ Services Offered
10.7.4 SWOT Analysis
10.8 Zhejiang Xianju Pharmaceutical Co., Ltd.
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Products/ Services Offered
10.8.4 SWOT Analysis
10.9 Shanghai Pharmaceutical Co., Ltd.
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
10.10 Reckitt Benckiser Group plc
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Products/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Subdermal Contraceptive Implants Market
Key Segments:
By Product
By Distribution Channel
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/enquiry/6653
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: https://www.snsinsider.com/enquiry/6653
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Sepsis Diagnostics Market was valued at USD 1.2 billion in 2023 and is expected to reach USD 2.5 billion by 2032, growing at a CAGR of 8.6% from 2024 to 2032.
The global Eyewear Market was valued at USD 189.93 billion in 2023 and is projected to grow at a CAGR of 7.65%, reaching USD 368.45 billion by 2032.
The Forensic Technology Market Size was valued at USD 4.50 Billion in 2023, and is expected to reach USD 10.80 Billion by 2032, and grow at a CAGR of 9.07% over the forecast period 2024-2032.
The Acromegaly Treatment Market was valued at USD 1.76 billion in 2023 and is expected to reach USD 2.88 billion by 2032, growing at a CAGR of 5.71% from 2024-2032.
The Electrosurgery Market Size was valued at USD 6.50 Billion in 2023 and is expected to reach USD 12.34 Billion by 2032 and grow at a CAGR of 7.76% over the forecast period 2024-2032.
Sterile Injectables CDMO Market size was valued at USD 3.89 billion in 2023 and is projected to reach USD 8.82 billion by 2032, expanding at a 9.54% CAGR.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
